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A B S T R A C T
A handheld approach to optoacoustic imaging is essential for the clinical translation. The ﬁrst 2- and 3-
dimensional handheld multispectral optoacoustic tomography (MSOT) probes featuring real-time
unmixing have recently been developed. Imaging performance of both probes was determined in vitro
and in a brain melanoma metastasis mouse model in vivo. T1-weighted MR images were acquired for
anatomical reference. The limit of detection of melanoma cells in vitro was signiﬁcantly lower using the
2D than the 3D probe. The signal decrease wasmore profound in relation to depth with the 3D versus the
2D probe. Both approaches were capable of imaging the melanoma tumors qualitatively at all time
points. Quantitatively, the 2D approach enabled closer anatomical resemblance of the tumor compared
to the 3D probe, particularly at depths beyond 3 mm. The 3D probewas shown to be superior for rapid 3D
imaging and, thus, holds promise for more superﬁcial target structures.
 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Multispectral optoacoustic tomography (MSOT) is an emerging
real-time optical biomedical imaging technique, providing non-
invasive, high resolution, intrinsic or contrast-enhanced, anatomi-
cal, functional and metabolic tomographic imaging at several
centimeters of tissue depth [1]. In principle, a nanosecond laser
pulse in the near-infrared (NIR) range induces molecules to
thermoelastically expand due to photon absorption. This short-
lasting expansion generates the emission of a pressurewave that is
detected by an ultrasonic transducer and converted into an image
[2]. Anatomical images are generated dependent on the absorption* Corresponding author at: Memorial Sloan Kettering Cancer Center, Department
of Radiology, and Center for Molecular Imaging & Nanotechnology (CMINT), 1275
York Ave, New York, NY 10065, USA. Tel.: +1 646 888-3371; fax: +1 646 422-0408.
E-mail address: kircherm@mskcc.org (M.F. Kircher).
http://dx.doi.org/10.1016/j.pacs.2015.12.001
2213-5979/ 2015 The Authors. Published by Elsevier GmbH. This is an open access artic
4.0/).contrast of different tissue structures in single wavelength images.
Multispectral images can yield metabolic information by resolving
spectral signatures of intrinsic tissue molecules or extrinsically
administered contrast agents absorbing at certain spectra.
Intrinsically, imaging of lipids and melanin concentration as well
as the oxygenation levels by oxygenated and deoxygenated
hemoglobin has been implemented by spectral unmixing based
on the unique signature of the components in the NIR spectrum
[3–5]. Extrinsic contrast agents such as small molecule dyes,
e.g. indocyanine green, ﬂuorescent proteins or nanoparticles can
signiﬁcantly enhance the optoacoustic contrast, allow deeper
tissue imaging and facilitate speciﬁc molecular processes to be
imaged [6–9]. We previously have shown the potential of gold
nanoparticles serving as a multimodal contrast agent in high grade
glioma imaging [9]. However, these studies as well as previous
multispectral optoacoustic tomography studies in various other
small animal models in neuroimaging [4,8], cancer [10,11] and
vascular disease research [12] so far have been based on complexle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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suitable for clinical translation [1,7]. Progress in the illumination
and detector technology has led to experimental MSOT setups for
potential handheld operation [13–16]. As a crucial step towards
clinical application, a 2- and a 3-dimensional handheld MSOT
probe have recently been developed, speciﬁcally designedwith the
aim of clinical translation. We studied the performance of these
new MSOT handheld-probes in vitro and in vivo in a melanoma
brain metastasis mouse model.
2. Material and methods
2.1. Handheld MSOT probe setup
The recently developed 3D cup-shaped handheld MSOT probe
(iThera Medical, Munich, Germany) consists of an array of
384 ultrasonic detector elements that are arranged on a spherical
surfacewith a radius of 40 mm towards the center of the sphere. It
allows an optimized tomographic coverage angle of 1208 with a
center frequency of 4 MHz (Fig. 1A). The fractional bandwidth
(6 dB) of the 3D detector was determined by the manufacturer to
be on average 58% in transmit/receive mode. The array follows
similar principles for 3D handheld optoacoustic tomography as
previously reported [16], but increased the number of detector
elements by 50% and the angular coverage by 308 to improve its
capabilities for potential clinical translation. Silica fused-endﬁber
bundles for illumination are ﬁxed in the center of the array and
coupled onto a 120-grid 1.6 mm thick diffuser (Edmunds Optics
Inc., Barrington, NJ, USA) for optimized scattered distribution of
light within the ﬁeld of view (FOV). The probe was integrated into
a stage controlledwater ﬁlled (deionized anddegased) animal bed
to control x,y,z translation during imaging, ensure constant[(Fig._1)TD$FIG]
Fig. 1. A. Upper Panel: Conﬁguration of the 3D-cup shaped handheld probe with a 384-el
is ﬁxed in the center of the array. The setup provides an axial (ax), sagittal (sag) and coro
sinus of a naı¨ve mouse brain (green arrows). Lower Panel: The ﬁeld of sensitivity around
the detector edge due to the cylindrical conﬁguration of the detector array. B. Upper Pane
detector array that covers an angle of 1358. In contrast to the 3D-approach it only allows
brain as shown here in reference to the corresponding coronal T2-weighted MRI (supe
Panel: This conﬁguration allows a broader ﬁeld of sensitivity around the center frequetemperature maintenance at 34 8Celsius as well as to facilitate
stable acoustic coupling. A 0.1 mm thin transparent polyvinyl
chloride membrane served as a cover and clear ultrasound gel as
ultrasonic couplant.
The recently developed 2D arc-shaped handheld MSOT probe
(iThera Medical, Munich, Germany) consists of a 2D array of
256 detector elements that are arranged along an arc on a spherical
surface (radius = 40 mm). It results in a greater coverage angle of
1358 at the same center frequency (4 MHz) (Fig. 1B). The
manufacturer determined the fractional bandwidth (6 dB) of the
2D detector to be on average 52% in transmit/receivemode. The 2D
probe was in principle based on a similar transducer array as
previously reported [13], but was improved to allow for potential
clinical applications, i.e. modiﬁcations to the size dimensions of the
array to provide a greater coverage angle, increasing the number of
detector elements by 50%, and adjusting the center frequency. The
fused-end light ﬁber bundles that guide the laser beam are ﬁxed
next to the center of gravity of the detector array at a 108 angle to
direct the illumination into the center of the FOV with the use of a
308 circular patterned diffusor (Luminit Co., Torrance, CA, USA)
coupled in between to allow laser beam shaping for sufﬁciently
even scattered light distribution. The shell of the probe is water
ﬁlled (deionized and degased) and sealedwatertight on the surface
by a thin transparent polyethylene membrane towards the FOV to
allow for acoustic coupling.
2.2. Illumination characterization
Both probes were connected to the same optoacoustic imaging
platform EIP10 (iThera Medical, Munich, Germany) designed for
experimental clinical use. This setup enabled quick plug-and-play
switching of the two handheld probes. The illumination beam isement spherical detector array that covers an angle of 1208. The illumination source
nal (cor) image plane in one set as demonstrated here showing the superior sagittal
the center frequency (4 MHz) is shown. The center of rotation is 16 mm apart from
l: Conﬁguration of the 2D-arc shaped handheld probewith a 256-element spherical
acquisition of one image plane per image set, e.g. the coronal plane of a naı¨vemouse
rior sagittal sinus = green arrow; brain circumference = dotted orange line). Lower
ncy (4 MHz) within the ﬁeld of view.
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parametric oscillator with a pulse duration of < 10 ns at a frame
rate of 10 Hz. In 2D, the optoacoustic signal generated by a single
laser pulse was simultaneously detected with the 256 detector
elements, in 3D with the 384 detector elements. The illumination
pattern of both probes was determined by translating an energy
meter (EnergyMax-USB J-50MB-YAG, Coherent) with an additional
aperture (3.5 mm in diameter) in front of the membranes of the
two probes. The resulting ﬂuence values were normalized to
generate ﬂuence maps. The measured illumination pattern was
ﬁtted with a 2D Gaussian function to determine the full width at
half maximum (FWHM) in order to allow a comparison of the
illumination pattern of both probes.
2.3. Resolution characterization
The resolution maps and the sensitivity ﬁelds were calculated
with the use of the ultrasound simulation program Field II (http://
ﬁeld-ii.dk/) inMATLAB (MathWorks Inc, Natick, MA, USA). At ﬁrst,
the signals of an array of optoacoustic point sources within the
ﬁeld of view were simulated with Field II with the shape, the
position, as well as the center frequency and bandwidth of
individual detector elements being taken into account. The
variation of the resulting signal amplitudes of the point sources
corresponds to the sensitivity ﬁeld of the detector array as shown
in Fig. 1. The images of individual point sources were recon-
structed from the simulated signals and the extension of the
resulting point-spread function was characterized by its full
width at half maximum (FWHM) along the direction with the
largest extension. The resulting point spread function FWHM
values of the simulated array of point sources were combined to
form the resolution maps. In order to obtain the out-of-plane
resolution of the 2D detector, optoacoustic point sources were
simulated outside of the imaging plane. The out-of-plane
resolution values were extracted from the FHWM of the signal
amplitude variation of optoacoustic point sources with a varying
distance to the imaging plane. In order to validate the simulation
results, the resolution was measured using black polyethylene
microspheres with an approximate diameter of 50 mm as
previously described [16].
2.4. MSOT image acquisition and processing
MSOT images were acquired multispectrally according to the
same protocol for both the 2D and 3D probe (21 wavelengths, 700-
900 nm in 10 nm intervals, average of 5 frames per wavelength).
While the ﬁeld of viewwas set to 25 x 25 mm for the 2D probe, the
ﬁeld of view of the 3D probe was 10 x 10 x 25 mm (X x Z x Y). A
pockels cell (Q-switch) delay (PCD) was increased from its optimal[(Fig._2)TD$FIG]
Fig. 2. A. The average laser energy output of the 2D and 3D probe across the NIR windo
distributed throughout all experiments) B. The optical absorption spectra of deoxygenated,
individual maximum OD within the wavelength range 700 to 900 nm.point to 250ms to reduce the overall laser energy for the whole
output spectrum in order to approximately meet the maximum
permissible skin exposure in humans as reported in the American
National Standard for Safe Use of Lasers [17] (2D: mean across
wavelengths 21.3  2.9 mJ/cm2; 3D: mean 23.1  3.1 mJ/cm2;
Fig. 2A). In order to compensate for different laser energies at
different wavelengths, an internal laser energy meter reading was
used. Both image data sets were reconstructed according to the same
algorithm with the use of the back-projection method in ViewMSOT
Software (V3.6, iThera Medical, Munich, Germany). After image
reconstruction, images corresponding to different wavelengths were
weighted with the internal laser energy values. The images were low
and high pass ﬁltered (50 kHz to 6.5 MHz) and the speed of soundwas
adjusted if appropriate: The natural round shape of small air bubble
inclusions in the agarose allowed for the appropriate adjustment in
vitro. In vivo, the round crossection of the prominent superﬁcial
sagittal sinus vein of the mice’s brain in the coronal plane served as
the target of appropriate speed of sound adjustment. Additionally,
the 2D image data were corrected for depth (background: 0.1 cm-1
absorption, 70% oxygenation). After reconstruction, the images were
spectrally decomposed by linear spectral unmixing on a pixel by pixel
basis (negative values discarded) based on the individual absorption
spectra of oxygenated and deoxygenated hemoglobin as well as
melanin in the NIR window (Fig. 2B). This was done to analyze for
the tissue content of melanin in all of the data as well as additionally
for oxygenated and deoxygenated hemoglobin, respectively, for the
in vivo data. Region of interest (ROI) analyses for MSOT signal
intensities as well as ROI sizes were determined by an independent
observer, blinded to the data acquisition.
2.5. In vitro model
A suspension of live B16F10 melanoma cells in phosphate
buffered saline (PBS) (1.8x105 cells/20ml PBS referred to
OD[800 nm] = 1) was used in a 1.5%-agarose phantom (0.002%/
vol. black ink and 1.2%/vol. 20%-intralipids added for scattering and
absorption) approximately mimicking the optical properties of
brain tissue in the NIR (absorption coefﬁcient ma  0.2 cm-1;
reduced scattering coefﬁcient (m’s 10 cm-1) [18,19] to determine
(1) the MSOT signal to concentration ratio of the cells in a dilution
series with PBS serving as negative control; (2) the signal to tissue
depth in increasing phantom thickness in relation to tissue
mimicking background; and (3) signal linearity over time at
constant cell concentration, constant tissue mimicking thickness
(3 mm) and constant illumination energy level, respectively. The
ROI sizes were set to a constant size for each probe to compare
the signal intensities of the B16F10 cell suspensions to the signal
of PBS and tissue mimicking background, respectively, as controls.
The direct comparison of signal values between the two probesw with the PCD adjusted to 250 ms (mean  SD represents n = 6 time points equally
oxygenated hemoglobin and melanin used for spectral unmixing, normalized to their
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signal of a constant absorber (OD = 1) that served as standard for
both probes.
2.6. In vivo model
We chose to use a local melanoma brain metastasis model for
this performance study due to (1) the excellent intrinsic
optoacoustic contrast of melanin, (2) the challenging optical
properties of brain tissue in situ, (3) well controllable, reproducible
and uniform tumor generation by stereotactic implantation, and
(4) because of its clinical relevance. In compliance with the local
animal care and use committee, four female albino C57BL/6NTac-
Tyrtm1Arte were stereotactically implanted with 2x105 isogeneic
luciferase-transfected B16F10 melanoma cells (suspended in 2 ml
PBS) into the right frontal lobe (1.0 mm posterior to bregma,
2.5 mm lateral to sagittal suture, at 2.5 mm depth). The mice
developed spherical tumors of 3.5-7 mm in diameter within
13 days. MSOT was sequentially performed transcranially on days
6, 8, 10 and 13 to monitor tumor growth, using 2.0% isoﬂurane
inhalation anesthesia. The 2D probe was rotated 908 in order to
obtain perpendicular planes (coronal and sagittal). The tumor sizes
were measured in their maximum extent in each dimension x, y, z
based on unmixed melanin signal in one data set for the 3D probe
while the image with the maximum tumor extent in each
dimension was separately chosen out of the stack of images
acquired with the 2D probe. The tumor extent was measured
according to the stated dimensions x and z in the coronal plane,
and the y dimension in the sagittal plane for both approaches. To
determine the test-retest reliability, the same mice were imaged
with the use of the 2D as well as the 3D probe on the same day
under the same conditions by the same observer repetitively three
times in a pseudo-randomized order (test 1, 2 and 3). The mice[(Fig._3)TD$FIG]
Fig. 3. A. Illumination pattern of the 3D probe: The ﬂuence values are shown as a normali
spot is 10 mmwith the light spot being symmetric. Cross sections of the measured and ﬁ
The illumination pattern of the 2D probewas found to be about 30% elongated in-plane an
probe.were fully removed from the ﬁeld of view between scans. Themice
were euthanized by carbon dioxide asphyxiation and the brain
tissue including tumors were harvested and processed in 4%
paraformaldehyde for further histological examination.
2.7. Magnetic resonance imaging (MRI)
Mouse brain 3D MR images were acquired in vivo on day
13 post implantation under 2.0% isoﬂurane inhalation anesthesia
with the use of a 4.7-Tesla Bruker USR animal scanner (Biospec 47/
40, Bruker Biospin Corp., Ettlingen, Germany) equipped with a
300mT/m gradient coil (20 cm inner diameter) and a custom-built
birdcage resonator (32 mm inner diameter): We obtained a 3D
isovoxel T1-weighted gradient echo sequence (FLASH) (echo/
repetition time (TE/TR) = 5.5/35 ms, FOV = 30x20x20 cm,
matrix = 192x128x128, isotropic resolution = 156 mm, ﬂip an-
gle = 458, averages = 4, acquisition time = 38.5 min) to serve as
anatomical reference standard in vivo for tumor size evaluations as
depicted by the maximum x and z dimensions of the tumor on the
coronal plane as well as the maximum extent on the y dimension
on the sagittal plane with the use of OsiriX software (V.5.5.1,
Pixmeo, Geneva, Switzerland). The maximum extent of the tumor
was deﬁned on the basis of the T1 signal alteration of the tumor in
relation to healthy mouse brain tissue in each plane.
2.8. Statistical analysis
Differences in MSOT signal intensities and ROI sizes between
the data acquired by the 2D and 3D probe were calculated
separately by the Student’s t-test. Results were considered
signiﬁcant when P was < 0.05 (Bonferroni-corrected for multiple
comparisons, if appropriate), as determined with the software
Prism (V6.0, GraphPad Inc., CA, USA). With regard to testing forzed ﬂuencemap. According to the 2D Gaussian ﬁt, the FWHM of the symmetric light
tted values around the probe output center along x and y are additionally shown. B.
d about 20% shortened out-of-plane compared to the symmetric light spot of the 3D
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separately determined by the calculation of the intraclass
correlation coefﬁcient (ICC) and its 95%-conﬁdence intervals (CI)
[20]. The accuracy of the approaches in vivo was individually
determined on the basis of tumor size resemblance in reference to
the MRI as standard and expressed as bias and its 95% limits of
agreement (LA) according to the Bland-Altman procedure [21].
3. Results
3.1. Fluence maps
The illumination pattern of the 3D probe was found to be a
symmetrical light spot with a FWHM of 10 mm (Fig. 3A). The
FHWM of the 2D probe’s illumination pattern was found to be
13.3 mm in the x dimension (elongated in-plane) and 8.1 mm for
the y dimension (shortened out-of-plane) (Fig. 3B). Overall, the
illuminated areas are very similar for both probes with the
difference of the areas above half maximum to be below 3%.
3.2. Resolution maps
At the center of rotation the optimal resolution of the 2D
transducer was found to be at approximately 200mm and, thus,
slightly higher than the optimal resolution of the 3D probe[(Fig._4)TD$FIG]
Fig. 4. A. 3D probe: The optimal resolution of the transducer, approximately 240 mm, is re
resolution gradually decreases with respect to distance from the center of rotation in the z d
relationship applies to the x and y dimension in equal terms due to the detector’s cylindr
The simulation results were validated by the resolution being measured with the use of blac
along the z-axis as previously described [16]. The resolution measurements were found to
B. 2D probe:With regard to the 2D detector conﬁguration, the in-plane resolution needs to b
in-planemaximum resolution reaches up to 200 mmclose to the center of rotation and remai
and z plane. The out-of-plane resolution dramatically decreases beyond approximately 
rotation.(approximately 240mm) (Fig. 4A and B). While the in-plane
resolution of the 2D probe was found to be stable  10 mm around
the center of rotation in the x and z plane (Fig. 4B), the 3D probe’s
resolution gradually decreases with respect to distance from the
center of rotation (Fig. 4A). In the y dimension (slice thickness)
however, the 2D probe’s out-of-plane resolution dramatically
decreases beyond approximately  1 mmout-of-plane (Fig. 4B)while
the resolution of the 3D probe behaves in the y dimension as it does in
the x dimension due to the cylindrical symmetry of the 3D transducer.
The accuracy of the simulation results could be validated by the
resolution measurements for the x and z plane with the use of black
microspheres (Fig. 4A).
3.3. Detection limits and signal stability in vitro
In a tissue mimicking phantom the limit of detection of a
dilution series of live B16F10 cells acquired by the 2D probe was
found to be 137 cells /ml PBS at 3 mm depth which was up to three
folds lower than with the 3D probe (412 cells /ml PBS) (Fig. 5A and
B). The cells could be detected by their signal difference to
background in a brain tissue mimicking phantom up to a depth of
16.5 mmwith the 2D probe and, thus, at least 2.5 mm deeper than
with the 3D probe (limit of detection: 14 mm). The rather ﬂat
signal derived from tissue mimicking phantom background was
found to be highest at the depth around the center of rotation of theached for target objects that are positioned  5 mmaround the center of rotation. The
imension as well as the x and y dimension due to the 3D detector elements’ array. This
ical symmetry.
k microspheres around the center of rotation of the detector array along the x-axis and
be in good agreement with the simulation results.
e distinguished from the out-of-plane resolution due to its limit to two dimensions. The
ns stable below 300 mm in a range of  10 mmaway from the center of rotation in the x
1 mm out-of-plane in the y dimension (slice thickness) with respect to the center of
[(Fig._5)TD$FIG]
Fig. 5. A. Comparison of the detection threshold of the 2D and 3D probe: MSOT signal (shown as maximum intensity projection, MIP) at 800 nm of a dilution series of B16F10
cells in 20ml PBS suspension inserted in a tissue mimicking phantom at 3 mm depth (scale: minimum to maximum). B. Signal to log-concentration plot of the detection
threshold for the 2D- and 3D- probe (n = 3, error bars = SD): The lowest density of cells which yielded a MSOT signal that signiﬁcantly differed from the PBS control solution
(2D: 2750  38 a.u.; 3D: 235  28 a.u.) were 137 cells /ml with the use of the 2D probe (2960  45 a.u., n = 3, P < 0.05) and 412 cells /ml with the 3D probe (1547  545 a.u., n = 3,
P < 0.05). C.MSOT signal of 7.4x104 B16F10 cells in 20 ml suspension in relation to depth in a tissue mimicking phantom of increasing thickness (n = 3, error bars = SD). D.MSOT
signal (at 800 nm) of 7.4x104 B16F10 cells in 20 ml suspension and tissue mimicking phantom background (3 mm depth) at constant multituned laser irradiation (700-900 nm in
10 nm steps) for 5 minutes (2D ROI = 1.35 mm2; 3D ROI = 1.16 mm2).
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characteristics of the probes on the signal intensity (Fig. 5C).
Throughout continuous multispectral laser irradiation (700-
900 nm) of 5 minutes the MSOT signal of the cell suspension as
well as the phantom’s background signal remained stable and no
signiﬁcant signal loss over time could be detected with either the
2D or the 3D probe (P > 0.1, Fig. 5D). Of note, the tissue mimicking
phantom’s normalized background MSOT signal itself was
signiﬁcantly higher when acquired with the 2D probe
(2692  44.2 a.u.) than with the 3D probe (587  92 a.u., n = 30,
P < 0.001) (Fig. 5D).
3.4. Accuracy and reliability in vivo
In vivo, both probes were capable of imaging the melanoma
brain metastases at all time points qualitatively (Fig. 6A and
Supplementary Figure S1). Quantitatively, throughout all three
dimensions the tumor extent was found to be of signiﬁcantly
greater size when imaged with the 2D (x = 6.19  1.10 mm;
y = 3.17  0.43 mm; z = 6.58  1.40 mm) compared to the 3D
probe (x = 3.95  0.77 mm, P < 0.05; y = 1.98  0.28 mm, P < 0.01;
z = 3.68  0.87 mm, P < 0.05, n = 4 each) when tumor sizes had
reached a mean diameter of approximately 5.5 mm as depicted by
MRI on day 13 post implantation (Fig. 6B, 6C and 7A). Tumors were
conﬁrmed as melanoma brain metastases by histological examina-
tion (Fig. 7B). Overall, in anatomical reference toMRI as standard in all
3 dimensions, the 2D probe proved more accurate in depicting the
tumor extent with an overall bias of only 0.24 mm [95%-LA: -3.35 to
3.82] compared to the 3D probe (bias = 2.35 mm [95%-LA: -0.6 to 5.3])
(Bland-Altman plots, Fig. 6D). Of note, with regard to the 2D probe
tumor extension beyond 4 mm in depth remarkably limited the
accuracy in depth (z dimension), while the accuracy for the x and y
dimensions was not affected by tumor size as such. With regard to
the 3D probe, however, the accuracy was limited beyond a tumor
size of 3.5 mm in all dimensions.In terms of precision, the in vivo test-retest reliability was
found to be comparably high for both approaches (2D:
ICC = 0.97 [0.90 – 0.99]; 3D: ICC = 0.89 [0.69 – 0.97]) (Fig. 8). With
regard to imaging acquisition time, the 3D-image acquisition was
less time consuming than the 2D approach due to less image
sets needed based on the simultaneous acquisition of the 3rd
dimension: One image set per mouse and day (acquisition time 
1 min, mean number of scans = 1) was sufﬁcient to depict the
tumor dimensions in total with the use of the 3D probe. The 2D
probe required at least two different image sets with the need for
repositioning the probe perpendicularly between scans (mean
acquisition time = 8.1  3.7 min, mean number of scans = 7.6  2.3,
n = 4, P < 0.001).
4. Discussion
We studied the performance of two recently developed
optoacoustic handheld probes with real-time multispectral
unmixing abilities, which were speciﬁcally developed with the
aim of clinical translation inmind. However, the approach of image
acquisition differs signiﬁcantly between the two systems - the 2D
probe and the 3D probe - which is reﬂected by the individual
performance. All 2D- and 3D- handheld approaches for multispec-
tral optoacoustic imaging that have been reported so far have been
based on prototypical experimental setups that were, as such, not
suitable for clinical applications. Such systems incorporated fewer
detector arrays, provided less angular coverage and/or were more
limited in resolution and imaging depth in real-time [13–
16,22,23]. In addition, with regard to clinical translation, the laser
energy level used to run those systems were either not explicitly
reported, acquired or may not havemet the maximum permissible
laser energy exposure threshold according to the American
National Standard for Safe Use of Lasers [17] as a similar laser
source was used in some studies as in the setup reported here but
[(Fig._6)TD$FIG]
Fig. 6. A. In vivoMSOT images of a naı¨ve and amelanoma bearingmouse brain acquiredwith the 2D probe (upper panel) and 3D probe (lower panel); shown are results at day
6 and day 13 after tumor inoculation (backgroundwavelength = 860 nm;melanin = green; oxygenated hemoglobin = red; deoxygenated hemoglobin = blue; superior sagittal
sinus = white arrow; skull base = orange arrow; A = anterior; P = posterior; C = caudal; L = left side; cor = coronal; sag = sagittal; ax = axial).While on day 6 the small spherical
volume of the melanin-containing tumor is depicted in total with both approaches, the tumor size on day 13 seems to limit the capability to depict the tumor volume as a
whole in both approaches due to saturation. B. Tumor size growth over time in days in the x, y, z dimensions (error bars = SD): While there was no signiﬁcant difference in
tumor size detected between both probes on day 6, when tumors were still small in size (P > 0.1), the difference in tumor size between the two probes increases gradually
over time. On day 13 post implantation, the tumor size measuredwith the 2D probewas signiﬁcantly greater in all three dimensions (x,y,z) thanwhenmeasured with the 3D
probe (* = P < 0.05). C. The mean tumor size measured with the 2D probe did not differ from the tumor size measured with T1-weighted MRI on day 13 post implantation
regarding the x and y dimension (P > 0.1, ns = non-signiﬁcant). With the regard to depth of the tumor (z dimension), the tumor size was found to be signiﬁcantly greater on
MRI than measured with either the 2D (P < 0.05) or the 3D probe (P < 0.05, error bars = SD). D. Bland-Altman plots of the accuracy of resembling the tumor extent on MSOT
images acquired by the 2D and 3D probe, respectively, vs. MRI as a standard on day 13 (95%-LA = 95% limits of agreement; x dimension = , y =~; z =&).
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the energy output accordingly [13,15,16].
According to our results, the 2DMSOT probe proved to be more
suitable than the 3D MSOT probe for handheld optoacoustic
imaging, particularly for highly absorbing and scattering tissue
targets at greater depths with regard to accuracy, reliability and
background signaling for spatial orientation. One might think that
the depth correction function that was applied to the 2D data may
have inﬂuenced the superior performance of the 2D probe at
greater depth. However, the signal enhancement within the area
where the target objects were placed was very subtle and limited
to up to 10% relative to the uncorrected values and could as such be
ruled out as a signiﬁcant cause for the difference found in tumor
assessments between the two probes (see Supplementary
Figure S2). One reason for the disadvantage of the 3D proberegarding these performance metrics may be the geometrically
suboptimal distribution of diffused light in the center of the
detector array. This likely limits the accuracy and imaging depth in
case of a strong light absorbing tissue target in the center of the
FOV, such as the challenging melanoma brain metastasis model
used in our study. On the other hand, the data for the 2D probe
indicate strong potential for clinical applications in various
scenarios, because the 2D probe enables 1) real-time handheld
MSOT operation similar to diagnostic ultrasound imaging, and 2)
fast wavelength tuning that allows excellent multispectral
unmixing of optoacoustic contrast in real-time at satisfactory
resolution and imaging depth. This provides enhanced background
signal for spatial orientation and yields high accuracy as well as
excellent test-retest reliability, even in optically challenging target
tissues. However, the 3D approach reported here holds promise for
[(Fig._7)TD$FIG]
Fig. 7. A. A 3D isovoxel T1 FLASH MRI sequence (TE/TR = 5.5/35 ms) served as reference standard in vivo for tumor size evaluations (cor = coronal; sag = sagittal; ax = axial;
R = right; L = left; A = anterior; P = Posterior; C = cranial). A lesion of varying intensity, mostly hypointense, could be identiﬁed at the site of implantation in all mice (dashed
green line). The MRI data was veriﬁed by histological correlation (example given in Figure B: dashed red line = corresponding plane to coronal section in Figure B, dashed
green line = tumor delineation). B. Histological examination with the use of hematoxylin & eosin (H&E) staining could conﬁrm the presence of a highly vascularized
melanoma brain metastasis (1x and 20x magniﬁcation). The brown pigment represents the typical appearance of focal deposition of melanin in a melanoma tumor (40x
magniﬁcation).
[(Fig._8)TD$FIG]
Fig. 8. Test-retest reliability: Each dot represents a single measurement of the maximum tumor extent in either the x, y or z dimension; each line connects to the respective
retest value. The overall test-retest reliability was found to be excellent for the 2D probe (ICC = 0.97 [0.90-0.99]) as well as high for the 3D probe (ICC = 0.89 [0.69-0.97]).
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dermatology, superﬁcial angiography or soft tissues with less
scattering and absorptive optical properties than brain and skull,
i.e. breast or subcutaneous fat and lymphatic tissue. Importantly,
immediate 3D visualization of the target tissue saves time
[15,24]. As different clinical scenarios may demand different
optoacoustic imaging approaches, this study expands the knowl-
edge of such capabilities and limitations of the recently developed
2D and 3D MSOT handheld probes. With regard to clinical
translation of the speciﬁc clinical scenario of melanoma detection
our study was limited in providing data about the unspeciﬁc
occurrence of unmixed melanin signal in biological tissues in the
absence of neoplasm that could potentially affect its limit of
detection in vivo. Overall, this study should help in further
improving suchMSOT systems in handheld operation on their way
towards clinical translation.
5. Conclusions
Both the 2D and 3D handheld MSOT systems provide real-time
multispectral unmixing and hold great promise for clinical
translation. The 2D MSOT handheld probe was found to provide
sufﬁcient resolution and sensitivity as well as high accuracy andreliability, even in highly absorbing and scattering target tissues. In
comparison, the 3D MSOT handheld probe added unique 3D
capabilities shortening imaging time, but was more limited in its
accuracy in scenarios with highly absorbing target tissues and at
greater tissue depths. Overall, the data resulting from this study
has identiﬁed speciﬁc strengths but also limitations of both
systems, which should aid in further improving their performance
before actual clinical translation begins.
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